Table 3.

Geometric mean titers (competitive Luminex immunoassay in milliMerck units) at blood draws 2 and 3 in study participants compared with the healthy cohort

HPV Genotype9–15 yr16–26 yr
CKDDialysisTransplantaHealthyCKDDialysisTransplantaHealthy
HPV 6
 BD2236 (n=10)877 (n=6)154 (n=8)929 (n=917)452 (n=8)103 (n=3)52 (n=13)545 (n=3329)
 BD3323 (n=11)44 (n=2)79 (n=5)156 (n=214)495 (n=10)48 (n=1)56 (n=3)109 (n=2788)
HPV 11
 BD257212262221304100033772749
 BD3355751072182045646137
HPV 16
 BD2209359164094918287113401372409
 BD317594171569441104352133442
HPV 18
 BD2317103261104342919936475
 BD319334381387152551
  • Competitive Luminex immunoassay used as general population (healthy) data from the licensing study was done using the competitive Luminex immunoassay (8). HPV, human papillomavirus; BD2, blood draw 2; BD3, blood draw 3.

  • a Wilcoxon rank sum test of differences in geometric mean titers: P=0.02 for patients with transplants versus healthy patients at BD2 for both 9- to 15-year-old and 16- to 26-year-old patients, P=0.06 for patients with transplants versus healthy patients at BD3 for 9- to 15-year-old patients, and P=0.15 patients with transplants versus healthy patients at BD3 for 16- to 26-year-old patients.